GSK and XenoPort's Horizant fails in Phase IIb for migraine prophylaxis
This article was originally published in Scrip
GlaxoSmithKline and XenoPort's new formulation of gabapentin, Horizant (gabapentin enacarbil, GSK1838262/XP13512), has failed to meet the primary endpoint in a Phase IIb study of improvement over placebo as a prophylactic treatment for migraine headaches, with or without aura. GSK told Scrip that it was probably not going to progress Horizant to Phase III for this indication.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.